{"entity":{"id":"nct07209111","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","aka":[],"tldr":"A phase 2 trial of Calderasib and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) is a phase 2 interventional study registered as NCT07209111 by Merck Sharp & Dohme LLC, with 150 participants planned, started 2025-12-04 and due to reach its primary completion in 2032-04-09. Interventions recorded: Calderasib and Cetuximab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07209111","url":"https://clinicaltrials.gov/study/NCT07209111"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["calderasib","cetuximab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07209111","phase":"2","setting":"A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)","sponsor":"Merck Sharp & Dohme LLC","enrolled":150,"outcomes":[]},"route":"/trials/nct07209111/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}